Screening Large Population Health Databases for Potential Coronavirus Disease 2019 Therapeutics: A Pharmacopeia-Wide Association Study of Commonly Prescribed Medications.

Derek R MacFaddenKevin BrownSarah E Wilson Hannah ChungRob KozakJeffrey C KwongDoug ManuelSamira MubarekaNick Daneman

Published in: Open forum infectious diseases (2022)

Using this epidemiologic approach, which can be applied to current and future pandemics, we have identified a variety of target drugs and drug classes that could offer therapeutic benefit in coronavirus disease 2019 (COVID-19) and may warrant further validation. Some of these agents (eg, fluoxetine) have already been identified for their therapeutic potential.

Keyphrases

coronavirus disease
respiratory syndrome coronavirus
small molecule
current status
sars cov
human health
adverse drug